These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 12693373)

  • 1. Metabolic complications associated with HIV disease.
    Sharp M
    Posit Aware; 2003; 14(2):32-6. PubMed ID: 12693373
    [No Abstract]   [Full Text] [Related]  

  • 2. [A case of lipo-atrophic diabetes].
    Romero E; Romero Bobillo E
    Rev Iber Endocrinol; 1970; 17(101):391-7. PubMed ID: 5501996
    [No Abstract]   [Full Text] [Related]  

  • 3. Lipoatrophy: a new "scarlet letter".
    Hoyt G
    Surviv News (Atlanta Ga); 2004; 15(2):8, 19. PubMed ID: 15124576
    [No Abstract]   [Full Text] [Related]  

  • 4. Metabolic complications of HIV therapy.
    Chow DC; Day LJ; Souza SA; Shikuma CM
    IAPAC Mon; 2006 Sep; 12(9):302-17. PubMed ID: 17378067
    [No Abstract]   [Full Text] [Related]  

  • 5. "Switch" studies for people with lipodystrophy.
    Proj Inf Perspect; 2000 Aug; (30):9. PubMed ID: 12171017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-associated lipodystrophy syndrome: an accelerated form of the metabolic syndrome of insulin resistance due to altered fat distribution.
    Balasubramanyam A; Sekhar RV
    Res Initiat Treat Action; 2006; 12(1):5-11. PubMed ID: 17153230
    [No Abstract]   [Full Text] [Related]  

  • 7. Metabolic complications in HIV infection. In search of underlying mechanisms.
    Johnson DL
    Adv Nurse Pract; 2002 Jul; 10(7):45-50, 76. PubMed ID: 12420551
    [No Abstract]   [Full Text] [Related]  

  • 8. The new AIDS paradigm: living with metabolic complications.
    Ferri RS
    Adv Nurse Pract; 2000 Sep; 8(9):69-70. PubMed ID: 11761555
    [No Abstract]   [Full Text] [Related]  

  • 9. Switching antiretroviral therapy: why, when and how.
    Wilkin T; Glesby M; Gulick RM
    IAPAC Mon; 2006 Jul; 12(7):220-9. PubMed ID: 17096494
    [No Abstract]   [Full Text] [Related]  

  • 10. Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival.
    Leonard EG; McComsey GA
    Infect Dis Clin North Am; 2005 Sep; 19(3):713-29. PubMed ID: 16102657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Control and treatment of HIV-associated lipodystrophy syndrome and related metabolic complications].
    Hansen BR; Haugaard SB; Nielsen JO; Madsbad S; Iversen J; Andersen O
    Ugeskr Laeger; 2003 Oct; 165(44):4218-20. PubMed ID: 14621554
    [No Abstract]   [Full Text] [Related]  

  • 12. Fat city: understanding HIV lipodystrophy.
    Flexner C
    Hopkins HIV Rep; 1998 Sep; 10(5):14-5. PubMed ID: 11365774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sublime versus simple side effect stories (or, forget the adiponectin, just stop smoking). 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. July 8-11, 2003, Paris.
    Mascolini M
    IAPAC Mon; 2003 Oct; 9(10):242-8, 252-61. PubMed ID: 14696574
    [No Abstract]   [Full Text] [Related]  

  • 14. Beta-cell dysfunction and low insulin clearance in insulin-resistant human immunodeficiency virus (HIV)-infected patients with lipodystrophy.
    Haugaard SB; Andersen O; Vølund A; Hansen BR; Iversen J; Andersen UB; Nielsen JO; Madsbad S
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):354-61. PubMed ID: 15730419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipodystrophy: no answers emerge in Durban.
    Pieribone D
    Posit Living; 2000 Aug; 9(7):19, 27. PubMed ID: 12492028
    [No Abstract]   [Full Text] [Related]  

  • 16. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
    Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A
    Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Where does insulin resistance in lipodystrophic HIV-1-positive subjects come from?
    Schmidt HH
    AIDS; 2001 Nov; 15(16):2187-8. PubMed ID: 11684939
    [No Abstract]   [Full Text] [Related]  

  • 18. HIV treatment series. Metabolic complications myths. Some misunderstandings about treatment.
    Wohl DA
    Posit Aware; 2007; 18(6):25-8. PubMed ID: 18069150
    [No Abstract]   [Full Text] [Related]  

  • 19. [Stigma, psychological stress and cardiovascular risk: long-term complications of lipodystrophy].
    MMW Fortschr Med; 2001 Aug; 143(33-34):53. PubMed ID: 11561461
    [No Abstract]   [Full Text] [Related]  

  • 20. Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations.
    Gougeon ML; Pénicaud L; Fromenty B; Leclercq P; Viard JP; Capeau J
    Antivir Ther; 2004 Apr; 9(2):161-77. PubMed ID: 15134178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.